Lung cancer in never smokers

Future Oncology

Volumn 7, Issue 10, 2011, Pages 1195-1211

  Torok, Szilvia ^a   Hegedus, Balazs ^b   Laszlo, Viktoria ^b   Hoda, Mir Alireza ^b   Ghanim, Bahil ^b   Berger, Walter ^b,c   Klepetko, Walter ^b   Dome, Balazs ^a,b   Ostoros, Gyula ^a  

^a NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

adenocarcinoma; carcinogenesis; causative factors; EGFR TKI; genetic susceptibility; lung cancer; mutations; never smoker

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ASBESTOS; BENZO[A]PYRENE; CARBOPLATIN; CETUXIMAB; CISPLATIN; COAL; CRIZOTINIB; CYTOCHROME P450 1A1; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ESTROGEN; ESTROGEN RECEPTOR; FORMALDEHYDE; FUEL; GEFITINIB; GEMCITABINE; HLA A ANTIGEN; HLA B ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; PACLITAXEL; POLONIUM; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; PROTEIN P63; RADON; RETINOL; TOBACCO SMOKE; UNINDEXED DRUG; URANIUM;

ADENOCARCINOMA; ASBESTOSIS; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CARCINOGENESIS; CHROMOSOME ABERRATION; CHRONIC LUNG DISEASE; CIGARETTE SMOKING; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; ESOPHAGUS CANCER; FIBROSING ALVEOLITIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HEAD AND NECK CANCER; HORMONE SUBSTITUTION; HUMAN; LUNG CANCER; LUNG DISEASE; MUTATION; OCCUPATIONAL EXPOSURE; ONCOGENE; PRIORITY JOURNAL; PROTEIN METHYLATION; REVIEW; SILICOSIS; SMOKING; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; WART VIRUS;

ANIMALS; CARCINOGENS; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; RISK FACTORS; SMOKING;

EID: 80054122591     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.100     Document Type: Review

References (201)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985 Int. J. Cancer 54(4), 594-606 (1993). (Pubitemid 23188190)
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008 GLOBOCAN 2008 Int. J. Cancer 127(12), 2893-2917
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002 CA Cancer J. Clin. 55(2), 74-108 (2005).
4. WHO. The Demographics of Tobacco. WHO, 94-101 (2011).
5. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat. Rev. Cancer 7(10), 778-790 (2007). (Pubitemid 47463669)
6. Yano T, Miura N, Takenaka T et al. Never-smoking non-small cell lung cancer as a separate entity. clinicopathologic features and survival. Cancer 113(5), 1012-1018 (2008).
7. Boffetta P, Jarvholm B, Brennan P, Nyren O. Incidence of lung cancer in a large cohort of nonsmoking men from Sweden. Int. J. Cancer 94(4), 591-593 (2001).
8. Thun MJ, Henley SJ, Burns D, Jemal A, Shanks TG, Calle EE. Lung cancer death rates in lifelong nonsmokers. J. Natl Cancer Inst. 98(10), 691-699 (2006). (Pubitemid 43832505)
9. Yano T, Haro A, Shikada Y, Maruyama R, Maehara Y. Non-small cell lung cancer in never smokers as a representative 'nonsmoking-associated lung cancer'. epidemiology and clinical features. Int. J. Clin. Oncol. 16(4), 287-293 (2011).
10. Scagliotti GV, Longo M, Novello S. Non-small cell lung cancer in never smokers. Curr. Opin Oncol. 21(2), 99-104 (2009).
11. Lee YJ, Kim JH, Kim SK et al. Lung cancer in never smokers. change of a mindset in the molecular era. Lung Cancer 72, 9-15 (2011).
12. Jindal SK, Malik SK, Dhand R, Gujral JS, Malik AK, Datta BN. Bronchogenic carcinoma in Northern India. Thorax 37(5), 343-347 (1982). (Pubitemid 12125190)
13. Badar F, Meerza F, Khokhar RA et al. Characteristics of lung cancer patients - the Shaukat Khanum Memorial experience. Asian Pac. J. Cancer Prev. 7(2), 245-248 (2006).
14. Henschke CI, Miettinen OS. Women's susceptibility to tobacco carcinogens. Lung Cancer 43(1), 1-5 (2004).
15. Henschke CI, Yip R, Miettinen OS. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA 296(2), 180-184 (2006). (Pubitemid 44050371)
16. Taioli E, Crofts F, Trachman J, Demopoulos R, Toniolo P, Garte SJ. A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung. Cancer Res. 55(3), 472-473 (1995).
17. Coté ML, Kardia SL, Wenzlaff AS, Ruckdeschel JC, Schwartz AG. Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer. JAMA 293(24), 3036-3042 (2005). (Pubitemid 40965074)
18. London SJ, Daly AK, Fairbrother KS et al. Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism. Cancer Res. 55(24), 6035-6037 (1995).
19. Thun MJ, Hannan LM, Adams-Campbell LL et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med. 5(9), e185 (2008).
20. Hong KU, Reynolds SD, Watkins S, Fuchs E, Stripp BR. Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium. Am. J. Pathol. 164(2), 577-588 (2004). (Pubitemid 38364673)
21. Coulson JM, Ocejo-Garcia M, Woll PJ. Neuroendocrine phenotype of small cell lung cancer. Methods Mol. Med. 74, 61-73 (2003).
22. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. J. Clin. Oncol. 13(5), 1215-1220 (1995).
23. Yokota J, Shiraishi K, Kohno T. Genetic basis for susceptibility to lung cancer: recent progress and future directions. Adv. Cancer Res. 109, 51-72 (2010)
24. Zheng B, Zhou J, Geng Q, Dong Q. A preliminary study on the origin of human lung adenocarcinoma stem cells from lung bonchioalveolar stem cells. Zhongguo Fei Ai Za Zhi 11(6), 759-764 (2008).
25. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am. J. Surg. Pathol. 29(5), 633-639 (2005). (Pubitemid 40577873)
26. Huxley R, Jamrozik K, Lam TH et al. Impact of smoking and smoking cessation on lung cancer mortality in the Asia-Pacific region. Am. J. Epidemiol. 165(11), 1280-1286 (2007). (Pubitemid 47234321)
27. Bae JM, Lee MS, Shin MH, Kim DH, Li ZM, Ahn YO. Cigarette smoking and risk of lung cancer in Korean men: the Seoul Male Cancer Cohort Study. J. Korean Med. Sci. 22(3), 508-512 (2007).
28. Stellman Sd, Takezaki T, Wang L et al. Smoking and lung cancer risk in American and Japanese men: an international case- control study. Cancer Epidemiol. Biomarkers Prev. 10(11), 1193-1199 (2001). (Pubitemid 33064308)
29. Brownson RC, Alavanja MC, Caporaso N, Simoes EJ, Chang JC. Epidemiology and prevention of lung cancer in nonsmokers. Epidemiol. Rev. 20(2), 218-236 (1998). (Pubitemid 29045108)
30. Maclure M, Katz RB, Bryant MS, Skipper PL, Tannenbaum SR. Elevated blood levels of carcinogens in passive smokers. Am. J. Public Health 79(10), 1381-1384 (1989). (Pubitemid 19239138)
31. Crawford FG, Mayer J, Santella RM et al. Biomarkers of environmental tobacco smoke in preschool children and their mothers. J. Natl Cancer Inst. 86(18), 1398-1402 (1994). (Pubitemid 24283359)
32. Subramanian J, Govindan R. Lung cancer in 'Never-smokers': a unique entity. Oncology (Williston Park) 24(1), 29-35 (2010).
33. Samet JM, Avila-Tang E, Boffetta P et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin. Cancer Res. 15(18), 5626-5645 (2009).
34. International Agency for Research on Cancer. Tobacco smoking and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans. IARC Press, Lyon, France 83 (2004).
35. Vineis P, Alavanja M, Buffler P et al. Tobacco and cancer: recent epidemiological evidence. J. Natl Cancer Inst. 96(2), 99-106 (2004). (Pubitemid 38195900)
36. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 315(7114), 980-988 (1997). (Pubitemid 27443125)
37. Kurahashi N, Inoue M, Liu Y et al. Passive smoking and lung cancer in Japanese nonsmoking women: a prospective study. Int. J. Cancer 122(3), 653-657 (2008). (Pubitemid 350308961)
38. Gilliland FD, Hunt WC, Archer VE, Saccomanno G. Radon progeny exposure and lung cancer risk among nonsmoking uranium miners. Health Phys. 79(4), 365-372 (2000).
39. Samet JM, Kutvirt DM, Waxweiler RJ, Key CR. Uranium mining and lung cancer in Navajo men. N. Engl. J. Med. 310(23), 1481-1484 (1984). (Pubitemid 14108843)
40. Roscoe RJ, Deddens JA, Salvan A, Schnorr TM. Mortality among Navajo uranium miners. Am. J. Public Health 85(4), 535-540 (1995).
41. Roscoe RJ, Steenland K, Halperin WE, Beaumont JJ, Waxweiler RJ. Lung cancer mortality among nonsmoking uranium miners exposed to radon daughters. JAMA 262(5), 629-633 (1989). (Pubitemid 19192239)
42. Belinsky SA, Klinge DM, Liechty KC et al. Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma. Carcinogenesis 25(6), 1063-1067 (2004). (Pubitemid 38886088)
43. Samet JM. Radon and lung cancer. J. Natl Cancer Inst. 81(10), 745-757 (1989). (Pubitemid 19137437)
44. Krewski D, Lubin JH, Zielinski JM et al. A combined analysis of North American case-control studies of residential radon and lung cancer. J. Toxicol. Environ Health A 69(7), 533-597 (2006).
45. Lubin JH, Boice JD Jr, Edling C et al. Lung cancer in radon-exposed miners and estimation of risk from indoor exposure. J. Natl Cancer Inst. 87(11), 817-827 (1995).
46. Darby S, Hill D, Auvinen A et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ 330(7485), 223 (2005).
47. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin. Oncol. 29(1), 2-17 (2002). (Pubitemid 34163530)
48. Mossman BT, Bignon J, Corn M, Seaton A, Gee JB. Asbestos: scientific developments and implications for public policy. Science 247(4940), 294-301 (1990). (Pubitemid 20046453)
49. Reid A, DE Klerk NH, Ambrosini GL, Berry G, Musk AW. The risk of lung cancer with increasing time since ceasing exposure to asbestos and quitting smoking. Occup. Environ. Med. 63(8), 509-512 (2006). (Pubitemid 44140199)
50. Camus M, Siemiatycki J, Meek B. Nonoccupational exposure to chrysotile asbestos and the risk of lung cancer. N. Engl. J. Med. 338(22), 1565-1571 (1998). (Pubitemid 28243985)
51. Reid A, Heyworth J, De Klerk N, Musk AW. The mortality of women exposed environmentally and domestically to blue asbestos at Wittenoom, Western Australia. Occup. Environ. Med. 65(11), 743-749 (2008).
52. Li S, Pan D, Wang G. Analysis of polycyclic aromatic hydrocarbons in cooking oil fumes. Arch. Environ. Health 49(2), 119-122 (1994).
53. Shields PG, Xu GX, Blot WJ et al. Mutagens from heated Chinese and U.S. cooking oils. J. Natl Cancer Inst. 87(11), 836-841 (1995).
54. Chiang TA, Wu PF, Wang LF, Lee H, Lee CH, Ko YC. Mutagenicity and polycyclic aromatic hydrocarbon content of fumes from heated cooking oils produced in Taiwan. Mutat. Res. 381(2), 157-161 (1997). (Pubitemid 28015411)
55. Yang SC, Jenq SN, Kang ZC, Lee H. Identification of benzo[a]pyrene 7,8-diol 9,10-epoxide N2-deoxyguanosine in human lung adenocarcinoma cells exposed to cooking oil fumes from frying fish under domestic conditions. Chem. Res. Toxicol. 13(10), 1046-1050 (2000).
56. Yu IT, Chiu YL, Au JS, Wong TW, Tang JL. Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women. Cancer Res. 66(9), 4961-4967 (2006).
57. Ko YC, Cheng LS, Lee CH et al. Chinese food cooking and lung cancer in women nonsmokers. Am. J. Epidemiol. 151(2), 140-147 (2000). (Pubitemid 30463644)
58. Kleinerman R, Wang Z, Lubin J, Zhang S, Metayer C, Brenner A. Lung cancer and indoor air pollution in rural china. Ann. Epidemiol. 10(7), 469 (2000).
59. Zhong L, Goldberg MS, Gao YT, Jin F. Lung cancer and indoor air pollution arising from Chinese-style cooking among nonsmoking women living in Shanghai, China. Epidemiology 10(5), 488-494 (1999). (Pubitemid 29398903)
60. Seow A, Poh WT, Teh M et al. Fumes from meat cooking and lung cancer risk in Chinese women. Cancer Epidemiol. Biomarkers Prev. 9(11), 1215-1221 (2000).
61. Zhao Y, Wang S, Aunan K, Seip HM, Hao J. Air pollution and lung cancer risks in China - a meta-analysis. Sci. Total Environ. 366(2-3), 500-513 (2006). (Pubitemid 44037686)
62. Metayer C, Wang Z, Kleinerman RA et al. Cooking oil fumes and risk of lung cancer in women in rural Gansu, China. Lung Cancer 35(2), 111-117 (2002). (Pubitemid 34136087)
63. Rehfuess E, Mehta S, Pruss-Ustun A. Assessing household solid fuel use: multiple implications for the Millennium Development Goals. Environ. Health Perspect. 114(3), 373-378 (2006). (Pubitemid 43338262)
64. Lan Q, Chapman RS, Schreinemachers DM, Tian L, He X. Household stove improvement and risk of lung cancer in Xuanwei, China. J. Natl Cancer Inst. 94(11), 826-835 (2002). (Pubitemid 34705054)
65. Mumford JL, He XZ, Chapman RS et al. Lung cancer and indoor air pollution in Xuan Wei, China. Science 235(4785), 217-220 (1987).
66. Sapkota A, Gajalakshmi V, Jetly DH et al. Indoor air pollution from solid fuels and risk of hypopharyngeal/laryngeal and lung cancers: a multicentric case-control study from India. Int. J. Epidemiol. 37(2), 321-328 (2008). (Pubitemid 351494209)
67. Luo RX, Wu B, Yi YN, Huang ZW, Lin RT. Indoor burning coal air pollution and lung cancer - a case-control study in Fuzhou, China. Lung Cancer 14(Suppl. 1), S113-S119 (1996). (Pubitemid 26094842)
68. Zhou BS, Wang TJ, Guan P, Wu JM. Indoor air pollution and pulmonary adenocarcinoma among females: a case-control study in Shenyang, China. Oncol. Rep. 7(6), 1253-1259 (2000).
69. Dai XD, Lin CY, Sun XW, Shi YB, Lin YJ. The etiology of lung cancer in nonsmoking females in Harbin, China. Lung Cancer 14(Suppl. 1), S85-S91 (1996).
70. Besso A, Nyberg F, Pershagen G. Air pollution and lung cancer mortality in the vicinity of a nonferrous metal smelter in Sweden. Int. J. Cancer 107(3), 448-452 (2003). (Pubitemid 37266466)
71. Zeka A, Mannetje A, Zaridze D et al. Lung cancer and occupation in nonsmokers: a multicenter case-control study in Europe. Epidemiology 17(6), 615-623 (2006). (Pubitemid 44655597)
72. Ko YC, Lee CH, Chen MJ et al. Risk factors for primary lung cancer among nonsmoking women in Taiwan. Int. J. Epidemiol. 26(1), 24-31 (1997).
73. Sobue T. Association of indoor air pollution and lifestyle with lung cancer in Osaka, Japan. Int. J. Epidemiol. 19(Suppl. 1), S62-S66 (1990). (Pubitemid 20321522)
74. Hernandez-Garduno E, Brauer M, Perez-Neria J, Vedal S. Wood smoke exposure and lng adenocarcinoma in nonsmoking Mexican women. Int. J. Tuberc. Lung Dis. 8(3), 377-383 (2004). (Pubitemid 38624876)
75. Behera D, Balamugesh T. Indoor air pollution as a risk factor for lung cancer in women. J. Assoc. Physicians India 53, 190-192 (2005). (Pubitemid 41280097)
76. Brenner DR, Mclaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS ONE 6(3), E17479 (2011).
77. Schabath MB, Delclos GL, Martynowicz MM et al. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am. J. Epidemiol. 161(5), 412-422 (2005). (Pubitemid 40315612)
78. Brenner DR, Hung RJ, Tsao MS et al. Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. BMC Cancer 10, 285 (2010).
79. Santillan AA, Camargo CA Jr, Colditz GA. A meta-analysis of asthma and risk of lung cancer (United States). Cancer Causes Control 14(4), 327-334 (2003). (Pubitemid 36735101)
80. Seow A, Ng DP, Choo S et al. Joint effect of asthma/atopy and an IL-6 gene polymorphism on lung cancer risk among lifetime nonsmoking Chinese women. Carcinogenesis 27(6), 1240-1244 (2006). (Pubitemid 43985439)
81. Alavanja MC, Brownson RC, Boice JD Jr, Hock E. Preexisting lung disease and lung cancer among nonsmoking women. Am. J. Epidemiol. 136(6), 623-632 (1992).
82. Gorlova OY, Zhang Y, Schabath MB et al. Never smokers and lung cancer risk: a case-control study of epidemiological factors. Int. J. Cancer 118(7), 1798-1804 (2006). (Pubitemid 43376446)
83. Bauer AK, Malkinson AM, Kleeberger SR. Susceptibility to neoplastic and nonneoplastic pulmonary diseases in mice: genetic similarities. Am. J. Physiol. Lung Cell Mol. Physiol. 287(4), L685-L703 (2004). (Pubitemid 39249381)
84. Hinds MW, Cohen HI, Kolonel LN. Tuberculosis and lung cancer risk in nonsmoking women. Am. Rev. Respir. Dis. 125(6), 776-778 (1982). (Pubitemid 12074601)
85. Zheng W, Blot WJ, Liao ML et al. Lung cancer and prior tuberculosis infection in Shanghai. Br. J. Cancer 56(4), 501-504 (1987). (Pubitemid 17146360)
86. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am. J. Respir. Crit. Care Med. 161(1), 5-8 (2000). (Pubitemid 30055895)
87. Wells C, Mannino DM. Pulmonary fibrosis and lung cancer in the United States: analysis of the multiple cause of death mortality data, 1979 through 1991 South Med. J. 89(5), 505-510 (1996). (Pubitemid 26142552)
88. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J. Clin. Oncol. 24(1), 59-63 (2006). (Pubitemid 46630494)
89. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin. Cancer Res. 10(1 Pt 1), 113-123 (2004). (Pubitemid 38114169)
90. Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women? Int. J. Epidemiol. 32(2), 263-271 (2003). (Pubitemid 36622273)
91. Blackman JA, Coogan PF, Rosenberg L et al. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol. Drug Saf. 11(7), 561-567 (2002). (Pubitemid 35345406)
92. Schwartz AG, Wenzlaff AS, Prysak GM et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J. Clin. Oncol. 25(36), 5785-5792 (2007).
93. Fasco MJ, Hurteau GJ, Spivack SD. Gender-dependent expression of a and b estrogen receptors in human nontumor and tumor lung tissue. Mol. Cell Endocrinol. 188(1-2), 125-140 (2002). (Pubitemid 34242672)
94. Schwartz AG, Prysak GM, Murphy V et al. Nuclear estrogen receptor b in lung cancer: expression and survival differences by sex. Clin. Cancer Res. 11(20), 7280-7287 (2005). (Pubitemid 41507685)
95. Wu CT, Chang YL, Shih JY, Lee YC. The significance of estrogen receptor b in 301 surgically treated non-small cell lung cancers. J. Thorac. Cardiovasc. Surg. 130(4), 979-986 (2005).
96. Kawai H, Ishii A, Washiya K et al. Estrogen receptor a and b are prognostic factors in non-small cell lung cancer. Clin. Cancer Res. 11(14), 5084-5089 (2005). (Pubitemid 41003691)
97. Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res. 65(4), 1598-1605 (2005). (Pubitemid 40270190)
98. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 36, 203-232 (1996). (Pubitemid 26168699)
99. Cavalieri E, Rogan E. Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture. Ann. NY Acad. Sci. 1089, 286-301 (2006). (Pubitemid 47092096)
100. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 65(4), 1459-1470 (2005). (Pubitemid 40270175)
101. Niikawa H, Suzuki T, Miki Y et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin. Cancer Res. 14(14), 4417-4426 (2008).
102. Cheng YW, Chiou HL, Sheu GT et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res. 61(7), 2799-2803 (2001).
103. Syrjanen KJ. HPV infections and lung cancer. J. Clin. Pathol. 55(12), 885-891 (2002). (Pubitemid 35454486)
104. Bohlmeyer T, Le TN, Shroyer AL, Markham N, Shroyer KR. Detection of human papillomavirus in squamous cell carcinomas of the lung by polymerase chain reaction. Am. J. Respir. Cell Mol. Biol. 18(2), 265-269 (1998). (Pubitemid 128355200)
105. Chen YC, Chen JH, Richard K, Chen PY, Christiani DC. Lung adenocarcinoma and human papillomavirus infection. Cancer 101(6), 1428-1436 (2004). (Pubitemid 39180399)
106. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J. Clin. Oncol. 25(5), 561-570 (2007). (Pubitemid 350002964)
107. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J. Clin. Oncol. 24(9), 1383-1388 (2006). (Pubitemid 46622002)
108. Kirk GD, Merlo C, O'Driscoll P et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin. Infect. Dis. 45(1), 103-110 (2007). (Pubitemid 46984625)
109. Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 360(9336), 861-868 (2002). (Pubitemid 35257961)
110. Ozasa K, Watanabe Y, Ito Y et al. Dietary habits and risk of lung cancer death in a large-scale cohort study (JACC Study) in Japan by sex and smoking habit.Jpn J. Cancer Res. 92(12), 1259-1269 (2001). (Pubitemid 34036888)
111. Koo LC. Dietary habits and lung cancer risk among Chinese females in Hong Kong who never smoked. Nutr. Cancer 11(3), 155-172 (1988).
112. Gustavsson P, Jakobsson R, Nyberg F, Pershagen G, Jarup L, Scheele P. Occupational exposure and lung cancer risk: a population-based case-referent study in Sweden. Am. J. Epidemiol. 152(1), 32-40 (2000). (Pubitemid 30637395)
113. Pierce DA, Sharp GB, Mabuchi K. Joint effects of radiation and smoking on lung cancer risk among atomic bomb survivors. Radiat. Res. 159(4), 511-520 (2003). (Pubitemid 36397773)
114. Richardson DB, Wing S, Wolf S. Mortality among workers at the Savannah River Site. Am. J. Ind. Med. 50(12), 881-891 (2007). (Pubitemid 350191442)
115. Nitadori J, Inoue M, Iwasaki M et al. Association between lung cancer incidence and family history of lung cancer: data from a large-scale population-based cohort study, the JPHC study. Chest 130(4), 968-975 (2006). (Pubitemid 44583723)
116. Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer among hospital patients. Public Health Rep. 78, 277-283 (1963).
117. Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer in humans. J. Natl Cancer Inst. 30, 289-312 (1963).
118. Ooi WL, Elston RC, Chen VW, Bailey-Wilson JE, Rothschild H. Increased familial risk for lung cancer. J. Natl Cancer Inst. 76(2), 217-222 (1986). (Pubitemid 16130001)
119. Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 96 million individuals in the Swedish Family-Cancer Database. Int. J. Cancer 99(2), 260-266 (2002). (Pubitemid 34309484)
120. Jonsson S, Thorsteinsdottir U, Gudbjartsson DF et al. Familial risk of lung carcinoma in the Icelandic population. JAMA 292(24), 2977-2983 (2004). (Pubitemid 39665298)
121. Schwartz AG, Yang P, Swanson GM. Familial risk of lung cancer among nonsmokers and their relatives. Am. J. Epidemiol. 144(6), 554-562 (1996). (Pubitemid 26304400)
122. Etzel CJ, Amos CI, Spitz MR. Risk for smoking-related cancer among relatives of lung cancer patients. Cancer Res. 63(23), 8531-8535 (2003). (Pubitemid 37549512)
123. Brownson RC, Alavanja MC, Caporaso N, Berger E, Chang JC. Family history of cancer and risk of lung cancer in lifetime nonsmokers and long-term ex-smokers. Int. J. Epidemiol. 26(2), 256-263 (1997). (Pubitemid 27190295)
124. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. Br. J. Cancer 93(7), 825-833 (2005). (Pubitemid 41486445)
125. Amos CI, Wu X, Broderick P et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q251 Nat. Genet. 40(5), 616-622 (2008). (Pubitemid 351601203)
126. Kohno T, Kunitoh H, Shimada Y et al. Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. Carcinogenesis 31(5), 834-841 (2010).
127. Landi MT, Chatterjee N, Yu K et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am. J. Hum. Genet. 85(5), 679-691 (2009).
128. Wang Y, Broderick P, Webb E et al. Common 5p1533 and 6p2133 variants influence lung cancer risk. Nat. Genet. 40(12), 1407-1409 (2008).
129. Li Y, Sheu CC, Ye Y et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol. 11(4), 321-330 (2010).
130. You M, Wang D, Liu P et al. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin. Cancer Res. 15(8), 2666-2674 (2009).
131. Liu P, Vikis Hg, Lu Y et al. Cumulative effect of multiple loci on genetic susceptibility to familial lung cancer. Cancer Epidemiol. Biomarkers Prev. 19(2), 517-524 (2010).
132. Hung RJ, Boffetta P, Brockmoller J et al. CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian nonsmokers: a pooled analysis. Carcinogenesis 24(5), 875-882 (2003). (Pubitemid 36748903)
133. Yoon KA, Kim JH, Gil HJ, Hwang H, Hwangbo B, Lee JS. CYP1B1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women. Lung Cancer 60(1), 40-46 (2008). (Pubitemid 351434467)
134. Kiyohara C, Wakai K, Mikami H, Sido K, Ando M, Ohno Y. Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: a case-control study in Japanese nonsmoking women. Int. J. Cancer 107(1), 139-144 (2003). (Pubitemid 37100098)
135. Bennett WP, Alavanja MC, Blomeke B et al. Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J. Natl Cancer Inst. 91(23), 2009-2014 (1999).
136. Gorlova OY, Weng SF, Zhang Y, Amos CI, Spitz MR, Wei Q. DNA repair capacity and lung cancer risk in never smokers. Cancer Epidemiol. Biomarkers Prev. 17(6), 1322-1328 (2008).
137. An Y, Jin G, Wang H et al. Polymorphisms in hMLH1 and risk of early-onset lung cancer in a southeast Chinese population. Lung Cancer 59(2), 164-170 (2008). (Pubitemid 351173405)
138. Fan LH, Chen JL, Cai L. Study on the association between DNA double-strand break repair gene NBS1 polymorphisms and susceptibility on lung cancer. Zhonghua Liu Xing Bing Xue Za Zhi 31(2), 213-217 (2010).
139. Osawa K, Miyaishi A, Uchino K et al. APEX1 Asp148Glu gene polymorphism is a risk factor for lung cancer in relation to smoking in Japanese. Asian Pac. J. Cancer Prev. 11(5), 1181-1186 (2010).
140. Qian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer 73(2), 138-146 (2010).
141. Zienolddiny S, Campa D, Lind H et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27(3), 560-567 (2006). (Pubitemid 43372885)
142. Ryk C, Kumar R, Thirumaran RK, Hou SM. Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers. Lung Cancer 54(3), 285-292 (2006). (Pubitemid 44634137)
143. Zhou W, Liu G, Miller DP et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 12(4), 359-365 (2003). (Pubitemid 36427997)
144. Lo YL, Hsiao CF, Jou YS et al. Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers. Lung Cancer 72(3), 280-286 (2010).
145. Thu KL, Chari R, Zhang W et al. Lung cancer genomes of smokers and never smokers harbor differential regions of copy number alteration. Presented at: AACR Frontiers in Cancer Prevention Research International Conference. Philadelphia, PA, USA, 7-10 November 2010
146. Matsuo K, Ito H, Yatabe Y et al. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci. 98(1), 96-101 (2007). (Pubitemid 44803926)
147. Shigematsu H, Takahashi T, Nomura M et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65(5), 1642-1646 (2005). (Pubitemid 40478587)
148. Matsumoto S, Takahashi K, Iwakawa R et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int. J. Cancer 119(6), 1491-1494 (2006). (Pubitemid 44258830)
149. Pham D, Kris MG, Riely GJ et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J. Clin. Oncol. 24(11), 1700-1704 (2006). (Pubitemid 46622141)
150. Lee YJ, Cho BC, Jee SH et al. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J. Clin. Oncol. 28(3), 487-492 (2009).
151. Tam IY, Chung LP, Suen WS et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin. Cancer Res. 12(5), 1647-1653 (2006).
152. Riely GJ, Kris MG, Rosenbaum D et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin. Cancer Res. 14(18), 5731-5734 (2008).
153. Soda M, Choi Yl, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153), 561-566 (2007). (Pubitemid 47206930)
154. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J. Clin. Oncol. 27(26), 4232-4235 (2009).
155. Koivunen JP, Mermel C, Zejnullahu K et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14(13), 4275-4283 (2008).
156. Wong DW, Leung EL, So KK et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115(8), 1723-1733 (2009).
157. Inamura K, Takeuchi K, Togashi Y et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod. Pathol. 22(4), 508-515 (2009).
158. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27(26), 4247-4253 (2009).
159. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010)
160. Le Calvez F, Mukeria A, Hunt JD et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 65(12), 5076-5083 (2005). (Pubitemid 40827316)
161. Husgafvel-Pursiainen K, Boffetta P, Kannio A et al. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res. 60(11), 2906-2911 (2000). (Pubitemid 30395814)
162. Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu X, Strong LC. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum. Genet. 113(3), 238-243 (2003). (Pubitemid 36992282)
163. Gealy R, Zhang L, Siegfried JM, Luketich JD, Keohavong P. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol. Biomarkers Prev. 8(4 Pt 1), 297-302 (1999). (Pubitemid 29193900)
164. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum. Mutat. 21(3), 229-239 (2003). (Pubitemid 36292965)
165. Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol. 9(7), 676-682 (2008). (Pubitemid 351878053)
166. Hainaut P, Pfeifer GP. Patterns of p53 G - >T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 22(3), 367-374 (2001). (Pubitemid 32203813)
167. Cappuzzo F, Varella-Garcia M, Shigematsu H et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J. Clin. Oncol. 23(22), 5007-5018 (2005). (Pubitemid 46224007)
168. Tomizawa K, Suda K, Onozato R et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer (2011) (Epub ahead of print).
169. Digel W, Lubbert M. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit. Rev. Oncol. Hematol. 55(1), 1-11 (2005). (Pubitemid 40779471)
170. Bowman RV, Yang IA, Semmler AB, Fong KM. Epigenetics of lung cancer. Respirology 11(4), 355-365 (2006). (Pubitemid 43824331)
171. Toyooka S, Maruyama R, Toyooka KO et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int. J. Cancer 103(2), 153-160 (2003). (Pubitemid 35461506)
172. Wang YC, Lu YP, Tseng RC et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J. Clin. Invest. 111(6), 887-895 (2003).
173. Kim DH, Nelson HH, Wiencke JK et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 61(8), 3419-3424 (2001). (Pubitemid 32695035)
174. Liu Y, Lan Q, Siegfried JM, Luketich JD, Keohavong P. Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 8(1), 46-51 (2006).
175. Toh CK, Gao F, Lim WT et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J. Clin. Oncol. 24(15), 2245-2251 (2006). (Pubitemid 46630653)
176. Shimizu H, Tominaga S, Nishimura M, Urata A. Comparison of clinico-epidemiological features of lung cancer patients with and without a history of smoking. Jpn J. Clin. Oncol. 14(4), 595-600 (1984).
177. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 126(2), 347-351 (2004). (Pubitemid 39093415)
178. Toh CK, Wong EH, Lim WT et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest 126(6), 1750-1756 (2004).
179. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 125(1), 27-37 (2004). (Pubitemid 38114560)
180. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
181. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced non-small cell lung cancer. Cancer 106(11), 2428-2436 (2006). (Pubitemid 43787667)
182. Scagliotti GV, Parikh P, Von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543-3551 (2008).
183. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527-1537 (2005). (Pubitemid 41540110)
184. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
185. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005). (Pubitemid 41058344)
186. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25(12), 1545-1552 (2007).
187. Balak MN, Gong Y, Riely GJ et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12(21), 6494-6501 (2006).
188. Bean J, Riely GJ, Balak M et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin. Cancer Res. 14(22), 7519-7525 (2008).
189. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007). (Pubitemid 46799492)
190. Sos ML, Koker M, Weir BA et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69(8), 3256-3261 (2009).
191. Guix M, Faber AC, Wang SE et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118(7), 2609-2619 (2008).
192. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet 373(9674), 1525-1531 (2009).
193. Khambata-Ford S, Harbison CT, Hart LL et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a Phase III study of cetuximab and first-line taxane/ carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 28(6), 918-927 (2010).
194. Truong T, Hung RJ, Amos CI et al. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J. Natl Cancer Inst. 102(13), 959-971 (2010).
195. Amos CI, Pinney SM, Li Y et al. A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. Cancer Res. 70(6), 2359-2367 (2010).
196. Pershagen G, Wall S, Taube A, Linnman L. On the interaction between occupational arsenic exposure and smoking and its relationship to lung cancer. Scand. J. Work Environ. Health 7(4), 302-309 (1981). (Pubitemid 12196452)
197. Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 132(1), 185-192 (2007). (Pubitemid 47068220)
198. Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA. Comparison of aspects of smoking among the four histological types of lung cancer. Tob. Control 17(3), 198-204 (2008).
199. Lee YJ, Shim HS, Kang YA et al. Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 136(12), 1937-1944 (2010).
200. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23(25), 5900-5909 (2005).
201. Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 13(10), 2890-2896 (2007). (Pubitemid 46849563)